TriSalus Life Sciences, Inc. (TLSI)
NASDAQ: TLSI · Real-Time Price · USD
5.03
+0.09 (1.82%)
Mar 4, 2026, 12:03 PM EST - Market open
TriSalus Life Sciences Employees
TriSalus Life Sciences had 110 employees as of December 31, 2024. The number of employees decreased by 2 or -1.79% compared to the previous year.
Employees
110
Change (1Y)
-2
Growth (1Y)
-1.79%
Revenue / Employee
$365,518
Profits / Employee
-$643,891
Market Cap
300.85M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 110 | -2 | -1.79% |
| Dec 31, 2023 | 112 | 37 | 49.33% |
| Dec 31, 2022 | 75 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Viemed Healthcare | 1,380 |
| RxSight | 498 |
| Quanterix | 471 |
| 908 Devices | 246 |
| Sight Sciences | 216 |
| Profound Medical | 142 |
| Senseonics Holdings | 117 |
| ClearPoint Neuro | 115 |
TLSI News
- 6 days ago - TriSalus Life Sciences to Host Fourth Quarter 2025 Financial Results Conference Call - Business Wire
- 12 days ago - TriSalus Life Sciences Announces Pricing of $40.0 Million Public Offering - Business Wire
- 12 days ago - TriSalus Life Sciences Proposes Public Offering - Business Wire
- 23 days ago - TriSalus Life Sciences Appoints Veteran Healthcare Investor Michael Stansky to its Board of Directors - Business Wire
- 7 weeks ago - TriSalus Life Sciences Announces Preliminary Fourth Quarter and Full-Year 2025 Results and 2026 Revenue Guidance - Business Wire
- 2 months ago - TriSalus Life Sciences, Inc. (TLSI) Discusses Innovative Approaches for Thyroid Artery Embolization and Tumor-Targeted Therapies Transcript - Seeking Alpha
- 3 months ago - TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Symptomatic Thyroid Disease on December 15, 2025 - Business Wire
- 3 months ago - TriSalus Life Sciences Launches TriNav® XP Infusion System to Expand Options for Pressure-Enabled Drug Delivery™ - Business Wire